List view / Grid view

News

Abeona Therapeutics completes cohort in Sanfilippo syndrome trial

30 August 2016 | By Niamh Louise Marriott, Digital Content Producer

The first-in-man clinical trial utilises a single injection of AAV gene therapy for patients with MPS IIIA (Sanfilippo syndrome type A), a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death...

RedHill Biopharma receives patent approval for MS drug

30 August 2016 | By Niamh Louise Marriott, Digital Content Producer

A first Phase III study with RHB-104 for the treatment of Crohn’s disease is currently ongoing, as well as a Phase IIa proof-of-concept study for the treatment of MS...

Novartis’ phase III MS study successfully meets endpoints

25 August 2016 | By Novartis

The study included 1,651 people with SPMS randomised to receive either 2mg BAF312 or placebo in a 2:1 ratio respectively, the primary endpoint being an improvement in the time to three-month confirmed disability progression, as measured by the expanded disability status scale (EDSS), versus placebo...

NICE approves CDF drugs for routine NHS use

24 August 2016 | By National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) issued final guidance recommending two drugs for routine use within the NHS: Bosutinib (Bosulif, Pfizer) for treating some patients with leukaemia and Pemetrexed (Alimta, Eli Lilly) for treating some patients with lung cancer...

ACG ACPL becomes first Asian company to receive EXCiPACT certification

24 August 2016 | By ACG Worldwide

ACG Worldwide is pleased to announce that ACG Associated Capsules Pvt. Ltd. (ACG ACPL) has received EXCiPACT certification for its plant at Dahanu – Maharashtra, India.  ACG ACPL is the first empty hard capsule manufacturing company in Asia to receive EXCiPACT certification. The certificate provides independent validation that ACG ACPL…

Pfizer to acquire AstraZeneca’s anti-infective business

24 August 2016 | By Pfizer

The agreement includes the rights to the newly approved EU drug zavicefta (ceftazidime-avibactam), the marketed agents merrem/meronem (meropenem) and zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL...

NICE says Bayer’s liver cancer drug is not cost-effective

24 August 2016 | By The National Institute for Health and Care Excellence (NICE)

NICE originally published guidance in 2010 which said that sorafenib was not cost effective but it was then made available through the CDF. NICE is reconsidering sorafenib as part of its programme to appraise drugs that are currently available...